Home Companies Newlystar (Ningbo) Medtech Co.,Ltd.

Levofloxacin Tablets Film coated Tablets, 250mg, 500mg Oral Medications Antibiotics

Contact Us

[China]

Trade Verify

Address: 801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China

Contact name:Luke Liu

Newlystar (Ningbo) Medtech Co.,Ltd.

Verified Suppliers
  • Trust
    Seal
  • Verified
    Supplier
  • Credit
    Check
  • Capability
    Assessment

Levofloxacin Tablets Film coated Tablets, 250mg, 500mg Oral Medications Antibiotics

Country/Region china
City & Province ningbo zhejiang

Product Details

Levofloxacin Tablets Film coated Tablets, 250mg, 500mg Oral Medications Antibiotics

 

Product : Levofloxacin Tablets

Specification : Film coated Tablets, 250mg, 500mg

Standard : BP, USP

Packing : 10’s/blister

 

Description :

Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral administration. Levofloxacin Tablets are available as film-coated tablets contains 500 mg (as expressed in the anhydrous form).

 

Indications and Usage :

To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

 

Levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed in this section.

 

Culture and susceptibility testing

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see CLINICAL PHARMACOLOGY (12.4)]. Therapy with levofloxacin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.

 

As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin tablets. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.

 

1.1 Nosocomial Pneumonia

Levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.

 

1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen

Levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.

 

MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥ 2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

 

1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen

Levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae.

 

1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens

Levofloxacin tablets are indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.

 

1.5 Acute Bacterial Exacerbation of Chronic Bronchitis

Levofloxacin tablets are indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.

 

1.6 Complicated Skin and Skin Structure Infections

Levofloxacin tablets are indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis.

 

1.7 Uncomplicated Skin and Skin Structure Infections

Levofloxacin tablets are indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.

 

1.8 Chronic Bacterial Prostatitis

Levofloxacin tablets are indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis.

 

1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen

Levofloxacin tablets are indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.

 

1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen

Levofloxacin tablets are indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa.

 

1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen

Levofloxacin tablets are indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.

 

1.12 Uncomplicated Urinary Tract Infections

Levofloxacin tablets are indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.

 

1.13 Inhalational Anthrax (Post-Exposure)

Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin tablets have not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk.

Hot Products

Oxymetazoline Hydrochloride Nasal Spray , 20 ml Nasal Drops 0.025% / 0.05% w/v Product : Oxymetazoli...
Azithromycin oral Suspension 200mg/5ml, 60ml Bottle, 100ml Bottle Oral Medications Dry Syrup Product ...
Amoxicillin and Clavulanate Potassium Tablets 250mg+125mg, 500mg+125mg, 875mg+125mg Oral Medications ...
Levofloxacin Tablets Film coated Tablets, 250mg, 500mg Oral Medications Antibiotics Product : ...
Roxithromycin Capsules Film coated Tablets, 150mg, 300mg Oral Medications Antibiotics Product : ...
Cefpodoxime Proxetil Tablets Film coated Tablets, 100mg, 200mg Oral Medications Antibiotics Product ...